Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3899/jrheum.131159 http://scihub22266oqcxt.onion/10.3899/jrheum.131159 24692523!ä!24692523 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Rheumatol 2014 ; 41 (5): 955-62 Nephropedia Template TP {{tp|p=24692523|t=2014. Effect of urate-lowering therapies on renal disease progression in patients with hyperuricemia |pdf=|usr=}}{{24692523}} gab.com Text Effect of urate-lowering therapies on renal disease progression in patients with hyperuricemia JO: J Rheumatol http://www.kidney.de/pget.php?&tw=1&pmid=24692523 #FOAvip OBJECTIVE: To evaluate the association between hyperuricemia and renal disease progression in a real-world, large observational database study. METHODS: We conducted a population-based retrospective cohort study identifying 111,992 patients with hyperuricemia (> 7 mg/dl) from a large medical group. The final cohort were >/= 18 years old, urate-lowering therapy (ULT)-naive, and had the following laboratory results available: at least 1 glomerular filtration rate (GFR) level before the index date and at least 1 serum uric acid (sUA) level and GFR in the followup 36-month period. The cohort was categorized into 3 groups: never treated (NoTx), ULT time receiving therapy of < 80% (< 80%), and ULT time receiving therapy of >/= 80% (>/= 80%). Outcomes were defined as a >/= 30% reduction in GFR from baseline, dialysis, or GFR of </= 15 ml/min. A subanalysis of patients with sUA < 6 mg/dl at study conclusion was performed. Cox proportional hazards regression model determined factors associated with renal function decline. RESULTS: A total of 16,186 patients met inclusion criteria. There were 11,192 NoTx patients, 3902 with < 80% time receiving ULT, and 1092 with >/= 80% time receiving ULT. Factors associated with renal disease progression were age, sex, hypertension, diabetes, congestive heart failure, hospitalizations, rheumatoid arthritis, and higher sUA at baseline. Time receiving therapy was not associated with renal outcomes. Patients who achieved sUA < 6 mg/dl had a 37% reduction in outcome events (p < 0.0001; HR 0.63, 95% CI: 0.5-0.78). CONCLUSION: Hyperuricemia is an independent risk factor for renal function decline. Patients treated with ULT who achieved sUA < 6 mg/dl on ULT showed a 37% reduction in outcome events. Twit Text FOAVip Effect of urate-lowering therapies on renal disease progression in patients with hyperuricemia ????J Rheumatol http://www.kidney.de/pget.php?&tw=1&pmid=24692523 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=24692523 #FOAvip English Wikipedia <ref>{{Cite pmid|24692523}}</ref> Effect of urate-lowering therapies on renal disease progression in patients with hyperuricemia #MMPMID24692523 Levy GD; Rashid N; Niu F; Cheetham TC J Rheumatol 2014[May]; 41 (5): 955-62 PMID24692523show ga OBJECTIVE: To evaluate the association between hyperuricemia and renal disease progression in a real-world, large observational database study. METHODS: We conducted a population-based retrospective cohort study identifying 111,992 patients with hyperuricemia (> 7 mg/dl) from a large medical group. The final cohort were >/= 18 years old, urate-lowering therapy (ULT)-naive, and had the following laboratory results available: at least 1 glomerular filtration rate (GFR) level before the index date and at least 1 serum uric acid (sUA) level and GFR in the followup 36-month period. The cohort was categorized into 3 groups: never treated (NoTx), ULT time receiving therapy of < 80% (< 80%), and ULT time receiving therapy of >/= 80% (>/= 80%). Outcomes were defined as a >/= 30% reduction in GFR from baseline, dialysis, or GFR of /= 80% time receiving ULT. Factors associated with renal disease progression were age, sex, hypertension, diabetes, congestive heart failure, hospitalizations, rheumatoid arthritis, and higher sUA at baseline. Time receiving therapy was not associated with renal outcomes. Patients who achieved sUA < 6 mg/dl had a 37% reduction in outcome events (p < 0.0001; HR 0.63, 95% CI: 0.5-0.78). CONCLUSION: Hyperuricemia is an independent risk factor for renal function decline. Patients treated with ULT who achieved sUA < 6 mg/dl on ULT showed a 37% reduction in outcome events. |Adrenal Cortex Hormones/therapeutic use[MESH] |Adult[MESH] |Aged[MESH] |Anti-Inflammatory Agents, Non-Steroidal/therapeutic use[MESH] |Colchicine/*therapeutic use[MESH] |Databases, Factual[MESH] |Disease Progression[MESH] |Female[MESH] |Follow-Up Studies[MESH] |Glomerular Filtration Rate/drug effects[MESH] |Gout Suppressants/therapeutic use[MESH] |Humans[MESH] |Hyperuricemia/*drug therapy/epidemiology/*metabolism[MESH] |Male[MESH] |Middle Aged[MESH] |Proportional Hazards Models[MESH] |Renal Insufficiency, Chronic/*drug therapy/epidemiology/*metabolism[MESH] |Retrospective Studies[MESH] |Risk Factors[MESH]Effect of urate-lowering therapies on renal disease progression in pat(epmc).pdf DeepDyve Pubget Overpricing